The Zilver PTX drug-eluting peripheral stent will be available in 40, 60, 80 and 100mm lengths and in 6 and 7mm diameters in Canada. The device has been designed to treat new or recurring lesions as long as 140mm per leg.

Zilver PTX is a self-expanding metal stent coated with the drug paclitaxel. The surrounding tissues absorb paclitaxel and prevent the growth of scar tissue that can reclog the artery.

Cook Medical Peripheral Intervention clinical division vice president Mark Breedlove said that launching Zilver PTX in Canada brings the benefits of drug-eluting stents to Canadian PAD patients.

Four-year clinical data from the randomized, international Zilver PTX trial demonstrated that 75% of patients treated with Zilver PTX maintained blood flow in the superficial femoral artery at four years. That compares to 57.9% patency for patients who were treated with a bare-metal Zilver stent.

According to Cook Medical, the Zilver PTX drug-eluting peripheral stent has been used to treat more than 25,000 peripheral arterial disease patients since its initial launch in 2009 in Europe.

Currently, Zilver PTX is available in more than 50 countries across Europe, the Middle East, North and South America, and the Asia-Pacific region.

Image: Cook Medical’s Zilver PTX drug-eluting peripheral stent to treat peripheral arterial disease in the superficial femoral artery. Photo: Courtesy of Cook Medical.